← Back to headlines
Bristol Myers Squibb, Hengrui Pharma Ink $15 Billion Licensing Deal
Bristol Myers Squibb and China's Hengrui Pharma have signed a licensing deal valued at up to $15.2 billion. This agreement involves a significant collaboration between the two pharmaceutical companies.
12 May, 06:38 — 12 May, 12:03
The Story
Analyzing sources…
Source Diversity
Source Diversity
Moderate (27/100)2 sources— more sources would strengthen this score15/33
Spectrum spread— 2/5 buckets covered8/33
Far L
Left
Center1
Center (1)
bloomberg
Right1
Right (1)
seeking-alpha
Far R
Geographic diversity— 1 region4/34
US2
ℹAll sources from US region
ℹOnly 2 sources cover this story
Sources
Showing 2 of 2 sources
bloombergHigh15d ago
Bristol-Myers Inks Up to $15 Billion Licensing Deal With Hengrui - Bloomberg.com
Bristol-Myers Inks Up to $15 Billion Licensing Deal With Hengrui Bloomberg.com
Read full article →seeking-alphaMixed15d ago
Bristol Myers and China’s Hengrui Pharma ink a licensing deal worth up to $15.2B
Read full article →Coverage Timeline
First report: bloomberg · 12 May, 06:38|Full coverage: 2 · 5h|Window: 5h
Left-leaningCenterRight-leaning
